Фенасал (Niclosamide) is an anthelmintic medication commonly used for the management and clearance of intestinal infections caused by various species of tapeworms (cestodes). Core indications include Taeniasis (beef and pork tapeworm), Hymenolepiasis (dwarf tapeworm), and Diphyllobothriasis (fish tapeworm). This medication is applied in clinical settings that involve established parasitic infections in both adults and pediatric patients.

---

Treatment Focus and Patient Benefit

The primary therapeutic benefit of this medication is that it provides support for the elimination of the parasite, and contributes to easing the overall symptom load. It is considered relevant when supportive symptom management is appropriate, particularly when the presence of the parasite creates noticeable physiological strain.

Upon addressing the parasitic burden, the medication may assist in easing symptom clusters like the visible passage of worm segments and contributes to easing related gastrointestinal discomfort and associated appetite disturbance. This provides supportive relief that supports patients during episodes of heightened discomfort and assists with supporting functional stability.

“This medication is commonly used across conditions presenting with acute episodes of cestode infestation, helping to manage the associated symptomatic burden.”

Quick Fact: Symptomatic Support for Intestinal Signs
May assist with addressing the visible manifestation of worm segments and assists in the management of related digestive distress.

Eligibility for Фенасал (Niclosamide) — Official Regulatory Information

Official regulatory guidelines strictly define the eligible and non-eligible populations for using Фенасал (Niclosamide), an anthelmintic agent. All individuals should review this information carefully.

---

Populations That Must Not Use the Medicine (Contraindications)

The only absolute contraindication is a known hypersensitivity or allergy to Niclosamide or any other component listed in the formulation. Anyone with a prior allergic reaction to the drug must not take it.

---

Age-Related Eligibility and Restrictions

Age Group	Eligibility Status (Regulatory Basis)
Children geq 2 years	Generally considered eligible, with no different safety profile reported in effective doses than in adults.
Children < 2 years	Safety and efficacy have not been formally established by some major regulatory bodies, limiting its routine use in this population.
Older Adults	Considered eligible; official regulatory documents report no specific information comparing use in the elderly to other age groups.

---

Pregnancy and Lactation Status

Niclosamide is classified as Pregnancy Category B (U.S. FDA, historical classification). Due to its minimal absorption from the gastrointestinal tract, major regulatory and public health bodies, including the World Health Organization (WHO), classify Niclosamide as compatible with breastfeeding, suggesting it poses minimal risk to the nursing infant.

Interactions with other medicines and products — Official Regulatory Information for Фенасал (Niclosamide)

Interaction Scope

The official interaction profile for Niclosamide is primarily defined by substance restrictions and specific administration timing. Due to the drug’s minimal systemic absorption, regulatory labels do not formally document significant systemic pharmacokinetic interactions with co-administered medicinal products involving major CYP enzymes or drug transporters.

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions:	None formally documented with other systemic medicinal products.
Mechanistic basis of interactions:	Pharmacodynamic interaction basis documented for alcohol restriction (additive effects).
Interaction-related restrictions:	Alcohol consumption is strictly prohibited during and immediately following treatment.

Interaction Classifications and Conditions

Official Interaction Statements:

• The co-administration of alcohol is formally prohibited. This is classified as a contraindicated co-administration to manage potential additive pharmacodynamic effects or to prevent the exacerbation of treatment-related adverse reactions.
• Regulatory guidance establishes a timing-based condition with food: the Niclosamide dose must be administered following a light meal to meet the official requirements for local drug exposure.

Connection to the overall interaction profile: The regulatory documents establish the drug's interaction structure around mandatory substance prohibition and an essential administration timing condition. This profile indicates a lack of known systemic drug-drug interactions that require dose adjustment or clinical monitoring based on current official labeling.

How Фенасал Works

Фенасал (Niclosamide) exerts its pharmacodynamic activity through two primary mechanistic domains: disruption of energy metabolism and modulation of key intracellular signaling pathways.

Mitochondrial Uncoupling and Energy Disruption

The principal action involves the uncoupling of oxidative phosphorylation within the mitochondria of targeted cells. Acting as an ionophore, Niclosamide disrupts the proton gradient across the inner mitochondrial membrane. The collapse of this electrochemical gradient inhibits the mitochondrial ATPase, preventing the synthesis of adenosine triphosphate (ATP). This sequence rapidly halts major metabolic processes, leading to the failure of energy-dependent cellular functions.

Modulation of Key Intracellular Signaling

Beyond energy disruption, Fenasal modulates several receptor- or enzyme-mediated signaling pathways in various biological contexts. It influences cascades such as the Wnt/beta-catenin and STAT3 pathways. This activity involves initiating or suppressing specific signaling sequences, thereby influencing feedback regulation within those intracellular systems.

How to Use Фенасал: Official Administration Guidelines

Фенасал (Niclosamide) is administered exclusively via the oral route as a tablet. The specific dosing regimen and preparation steps are governed by the tapeworm species being treated and are outlined in regulatory guidelines.

---

Administration and Preparation

For proper use, the tablet must be thoroughly chewed or crushed into a fine powder before being swallowed. This prepared dose should be taken with a small amount of water. Administration is generally advised after a light meal to mitigate potential gastrointestinal discomfort.

Official Dosing Regimens

Indication	Adult Dosing Schedule
Beef, Pork, and Fish Tapeworm	2 grams administered as a single oral dose.
Dwarf Tapeworm (Hymenolepis nana)	2 grams on Day 1, followed by 1 gram daily for the subsequent 6 days.

Population-Specific and Procedural Conditions

Pediatric dosing is calculated proportionally based on the patient’s body weight or assigned to age/weight tiers, as defined in the official prescribing information. The tablet is often crushed and mixed with water to form a paste for children.

For the treatment of Pork tapeworm (Taenia solium), official instructions recommend following the dose with a saline purgative approximately two hours later. If a patient experiences vomiting after the initial single dose, the dose may be divided into two portions and taken one hour apart to ensure full intake.

Research evidence / Overview of studies for Фенасал (Niclosamide)

The research foundation for Фенасал, or Niclosamide, is primarily built upon clinical trials and analyses focused on evaluating the measured outcome of parasite clearance for specific types of parasitic tapeworms from the digestive tract. The evidence contributes to understanding what has been observed so far in study settings regarding parasite clearance and symptom patterns.

---

Evidence for use in Taeniasis (Beef and Pork Tapeworm)

The use of Niclosamide for infections caused by Taenia saginata and Taenia solium was studied for controlled trials, including older randomized studies, and systematic reviews. Research examined the outcomes related to parasite clearance, which is defined by the absence of tapeworm segments or eggs in stool samples, in both adults and pediatric patients. Findings describe patterns observed in the studies related to clearance rates. Follow-up durations were often limited, contributing to uncertainty in long-term outcomes.

---

Evidence for use in Hymenolepiasis (Dwarf Tapeworm)

Research exploring the use of Niclosamide for the dwarf tapeworm (Hymenolepis nana) was evaluated in various clinical trials and case series. The main outcome was studied for the Parasitological Cure Rate, with studies observing outcomes following the necessary multi-day dosing regimen. The risk of re-infection in this condition was observed in some studies, which may complicate the evaluation of measured outcomes.

---

Evidence for use in Diphyllobothriasis (Fish Tapeworm)

The use of Niclosamide for Diphyllobothriasis (fish tapeworm) was evaluated in clinical trials and supported by regulatory clinical evaluation records. Research examined the outcomes related to confirmed absence of the parasite in both adult and pediatric patients. The evidence base for this tapeworm type was primarily derived from older and smaller studies.

---

Research Gaps and Limitations

The overall research landscape has several limitations. Evidence quality varies across studies, with a noted reliance on older research that may be characterized by a higher risk of methodological bias and modest sample sizes. Long-term effects are not fully established, as follow-up durations were limited in many primary studies. Furthermore, comparative evidence is lacking in many areas, and data for certain groups remain insufficient, specifically concerning pregnant populations or those with significant coexisting health conditions.

Key Studies & References Niclosamide: Drug Information (Supports use, populations, and low systemic absorption)

Common questions about Фенасал (FAQ)

Q: Is Фенасал a prescription medication or over-the-counter?

The active ingredient, Niclosamide, is generally classified by global health authorities as a prescription-only medicine (Rx). However, the specific legal status for buying and dispensing the drug is determined by the local regulatory bodies in each country.

Q: What common over-the-counter drugs should not be taken with Фенасал?

Official regulatory documents indicate that there are no significant systemic drug-drug interactions documented with co-administered medicinal products, which is consistent with the drug's minimal absorption into the bloodstream. It is essential to remember that alcohol consumption is strictly prohibited during and immediately following treatment.

Q: Does Фенасал have any known effect on blood pressure?

Changes in blood pressure, such as hypertension or hypotension, are not listed among the officially documented or reported adverse reactions for Niclosamide in regulatory safety sections. The medicine’s design for low systemic absorption contributes to its local action.

Q: Is Фенасал safe for people who have existing kidney problems?

Official regulatory documents do not contain specific warnings or requirements for dose adjustments related to kidney impairment. This is consistent with the fact that the drug is minimally absorbed into the bloodstream and acts locally in the gastrointestinal tract.

Q: Can people with diabetes or other chronic conditions use Фенасал?

Regulatory information does not list chronic conditions such as diabetes or common heart and respiratory conditions as specific contraindications. Only a known hypersensitivity or allergy to the drug or any of its components is considered an absolute contraindication in official labeling.

Q: Does Фенасал affect liver function or require liver monitoring?

There is no officially documented adverse reaction involving liver toxicity (hepatotoxicity), and official regulatory documents do not specify a requirement for routine liver function monitoring. This is due to the drug’s minimal passage into the systemic circulation.

Q: Can people with a history of heart conditions take Фенасал?

Official regulatory labeling contains no specific contraindications or warnings related to pre-existing heart conditions or cardiovascular risk factors. This profile is consistent with the drug's minimal passage into the systemic circulation.

Q: What is the general guidance if a scheduled dose of Фенасал is missed?

Official guidance typically directs the user to contact their healthcare provider immediately for individualized advice. This measure is generally consistent with following the specific dosing regimen prescribed for the infection being treated.

Q: Is Фенасал considered a drug that is habit-forming or addictive?

Regulatory documents contain no information or statements concerning abuse, dependence, or habit-forming potential for Niclosamide. The drug is not classified as a controlled substance.

Q: Are there different brand names used for the drug Фенасал?

Yes, the active ingredient Niclosamide has been marketed internationally under various brand names. These brand names may include Yomesan, Niclocide, and Lintex, depending on the region where it is sold.

Q: Which international regulatory bodies have reviewed or approved Фенасал?

Niclosamide is included on the World Health Organization's List of Essential Medicines (WHO). Its use is regulated by major health authorities worldwide, including the US FDA, Health Canada, and national bodies within the European Medicines Agency (EMA) system.

Q: Is there evidence that the effectiveness of Фенасал decreases with extended use?

Official regulatory documents do not contain information indicating a recognized risk of decreased effectiveness. This means there is no documented concern for pharmacological tolerance or parasite resistance associated with its approved use.

How to Store and Dispose of Fen*asal (Niclosamide)

Fen*asal tablets must be stored according to regulatory labeling to maintain product stability and safety. The required storage condition is controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), though temporary excursions between 15 C and 30 C are permitted.

---

Required Storage and Handling

The medication must be protected from environmental factors. It should be kept in a closed container and stored away from heat, direct light, and moisture. Freezing the tablets is prohibited. As a mandatory safety requirement, Fen*asal must be kept out of the reach of children, and any outdated medicine should be discarded.

Disposal

The official instructions require that the unused portion of the medication and any potentially contaminated patient excreta must be disposed of by following local sanitary regulations.